lenrispodun (ITI-214) / Intra-Cellular Therapies 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   63 News 
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Journal:  Selective PDE1 inhibition ameliorates vascular function, reduces inflammatory response, and lowers blood pressure in ageing animals. (Pubmed Central) -  Dec 25, 2021   
    In the present study, we studied the effect of acute and chronic treatment with ITI-214, a selective phosphodiesterase 1 inhibitor on vascular aging features in Ercc1 mice...These findings suggest PDE1 inhibition would provide a powerful tool for nitric oxide - cGMP augmentation and have significant therapeutic potential to battle arteriopathy related to ageing. Significance Statement The findings implicate the key role of PDE1 in vascular function and might be of clinical importance for prevention of mortalities and morbidities related to vascular complications during ageing, as well as for progeria patients that show a high risk of cardiovascular disease.
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Trial completion, Trial completion date, Trial primary completion date:  Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure (clinicaltrials.gov) -  Dec 24, 2020   
    P1/2,  N=36, Completed, 
    Translating these findings to humans suggests that ITI-214 may provide a means to expand the utility of immune checkpoint inhibitors in immunogenic tumors. Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  ITI-214 - Intra / Cellular Therapies, ITI / 214
    Journal:  Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses. (Pubmed Central) -  Nov 7, 2020   
    These studies are the first to demonstrate that inhibition of PDE1 exerts anti-inflammatory effects through effects on microglia signaling pathways. The ability of PDE1 inhibitors to prevent or dampen excessive inflammatory responses of BV2 cells and microglia provides a basis for exploring their therapeutic utility in the treatment of neurodegenerative diseases associated with increased inflammation and microglia proliferation such as Parkinson's disease and Alzheimer's disease.
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Trial completion:  Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement (clinicaltrials.gov) -  Nov 14, 2019   
    P1,  N=26, Completed, 
    We propose a novel mechanism that PDE1 modulates sl cAMP to increase LTCC and to induce contractility. Active, not recruiting --> Completed
  • ||||||||||  Journal:  Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition: A Translational Study in the Dog and Rabbit. (Pubmed Central) -  Oct 2, 2019   
    ITI-214 effects were additive to β-adrenergic receptor agonism (dobutamine)...In rabbits, β-adrenergic receptor blockade (esmolol) prevented ITI-214-mediated chronotropy, but inotropy and vasodilation remained unchanged...The effects appear related to cAMP signaling that is different from that provided via beta-AR receptors or PDE3 modulation. ITI-214, which has completed Phase I trials, may provide a novel therapy for HF.
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Enrollment closed:  Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement (clinicaltrials.gov) -  Jun 28, 2019   
    P1,  N=26, Active, not recruiting, 
    ITI-214, which has completed Phase I trials, may provide a novel therapy for HF. Recruiting --> Active, not recruiting
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure (clinicaltrials.gov) -  Jul 26, 2018   
    P1/2,  N=36, Recruiting, 
    Trial primary completion date: May 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Trial completion date: Jul 2019 --> Dec 2019 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  lenrispodun (ITI-214) - Intra / Cellular Therapies
    Enrollment open:  Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement (clinicaltrials.gov) -  Jul 26, 2018   
    P1,  N=25, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jul 2019 --> Dec 2019 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jul 2019 --> Dec 2019 Not yet recruiting --> Recruiting